Related Articles
A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles
Safety and efficacy of carboplatin plus nab-paclitaxel for treating advanced non-small-cell lung cancer with interstitial lung disease
Weekly vs. 3‑weekly paclitaxel, carboplatin, and cetuximab (PCC) in recurrent/metastatic head and neck cancer
Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis
Randomized phase II study of sequential carboplatin plus paclitaxel and gefitinib in chemotherapy‑naïve patients with advanced or metastatic non‑small‑cell lung cancer: Long‑term follow‑up results